$VKTX

Multiple outlets discuss GLP-1 competition and recent updates for Viking Therapeutics (VKTX). Zacks reports VKTX Q2 results beat loss estimates despite higher R&D costs. Stocktwits says VKTX launched a $500M shelf after full enrollment of a Phase 3 obesity study, with proceeds for VK2735 development. Other items cover NVO and LLY outlooks.

Viking Therapeutics (NASDAQ: VKTX) shares fell 18.6% in July as investors focused on cash burn and potential dilution. The company reported Q2 cash use of about $96 million and ended with $502 million cash, down from $706 million. It also filed an SEC registration for up to $500 million in common stock. Phase 3 trials for VK2735 are enrolled, with VK2736 maintenance results expected this quarter.

Viking Therapeutics (NASDAQ: VKTX) shares fell 18.6% in July, with investors citing concerns about funding for its pipeline. In late July, the company reported Q2 results and said phase 3 VK2735 (subcutaneous) is fully enrolled, phase 3 (oral) starts in Q4, and phase 1 VK2736 maintenance reports this quarter. Cash burn was about $96M, ending with $502M cash, down from $706M, and the company filed an SEC registration to sell up to $500M common stock.

Raymond James updated its August healthcare top picks, adding Aveanna Healthcare (AVAH) ahead of its Aug. 13 earnings, and Carriage Services (CSV) after a ~20% decline since April, citing stabilizing funeral trends and valuation around 8x 2027 estimated EBITDA. It also added Viking Therapeutics (VKTX) for upcoming clinical readouts.

The article highlights three biotech stocks for August and later catalysts. Regeneron (REGN) is cited as down about 11% YTD despite Q1 2026 revenue of $3.605B and non-GAAP EPS $9.47, plus a $3.0B buyback. Moderna (MRNA) is noted for a Q1 2026 revenue jump to $389M and an Aug. 5 FDA PDUFA for flu vaccine mRNA-1010. Viking Therapeutics (VKTX) is pre-revenue with Phase 3 obesity trials and a $92.58 analyst target.

Viking Therapeutics (VKTX) reported a wider Q2 2026 net loss of $128.02 million and filed a universal shelf registration plus a $500 million at-the-market common stock offering, expanding funding options. The article links these moves to investor expectations for VK2735 obesity drug development, noting dilution and cash burn risks and citing forecasts of $118.5 million revenue and $12.9 million earnings by 2029.

U.S. stock futures edged lower ahead of PCE inflation and jobless claims. Big Tech earnings were mixed as AI capex plans rose, with Meta, Microsoft, Alphabet, Amazon, Qualcomm, Intel, and Apple highlighted. Oil jumped on reports of potential U.S. strike options against Iran, lifting USO about 128% YTD. VKTX and HOOD also drew attention.

Viking Therapeutics (VKTX) shares fell 4.49% to $31.93 after the company reported a Q2 net loss of $1.10 per share, better than the $1.25 expected, but higher than a year ago. R&D nearly doubled to $115.8M. Cash and short-term investments were $502M. Canaccord kept a Buy and raised its price target to $114. Upcoming study data and VK2735 Phase 2 results are cited.

Viking Therapeutics VKTX reported a second-quarter 2026 loss of $1.10 per share, narrower than the Zacks Consensus Estimate of a loss of $1.21. The reported loss, however, widened from a loss of 58 cents per share in the year-ago quarter due to higher operating expenses. Viking does not have any approved product in its portfolio and is yet to generate revenues. The company continued investing in VK2735, its lead obesity candidate being developed in injectable and oral formulations.

Canaccord raised the firmâs price target on Viking Therapeutics (VKTX) to $114 from $107 and keeps a Buy rating on the shares. The firm said the company beat on the bottom line, reporting a loss of $1.10 per share compared to estimates of a $1.35 per share loss and the consensus estimate of a $1.23 per share loss. Management guided for lower cash expenditure in 2027 but is actively expanding their workforce.